Evidence map›Paper›PMID 42808078›Full record

ArticleJournal of research in pharmacy practice2026

Clinical Outcomes of Adding Topical Cetirizine to Minoxidil Therapy in Patients with Androgenetic Alopeci.

Fatemeh Mokhtari, Gita Faghihi, Somayeh Maleki, Sayed Mohsen Hosseini, Parvane Sadeghi Dolatabadi

Abstract read
In one paragraph

Article in Journal of research in pharmacy practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fatemeh MokhtariDepartment of Dermatology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Gita FaghihiDepartment of Dermatology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Somayeh MalekiDepartment of Dermatology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Sayed Mohsen HosseiniDepartment of Biostatistics and Epidemiology, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran.
Parvane Sadeghi DolatabadiDr. Sadeghi Dolatabadi Pharmacy, Dr. Shariati Street, No. 181, Ground Floor, Shahid Bijan Vaezi Alley, Sichan District, Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The objective is to evaluate the efficacy and safety of adding 1% topical cetirizine to 5% topical minoxidil compared with topical minoxidil alone in patients with androgenetic alopecia (AGA). Methods: In this single-blind randomized clinical trial, 62 patients with AGA were allocated to receive either topical minoxidil 5% twice daily (monotherapy group, Findings: Both groups demonstrated improvement from baseline in hair density and hair diameter scores after 16 weeks of treatment. However, no significant differences were observed between groups in hair density score (0.65 ± 0.61 vs. 0.68 ± 0.60, Conclusion: The addition of 1% topical cetirizine to topical minoxidil did not result in superior objective hair-growth outcomes compared with minoxidil alone. Although patient satisfaction was higher among patients receiving adjunctive cetirizine, this finding may be attributable to factors other than a direct pharmacologic effect. Further double-blind, vehicle-controlled studies with larger sample sizes are warranted to clarify the role of topical cetirizine in the management of AGA.

Indexed as

Androgenetic alopeciacetirizineminoxidilrandomized clinical trialtrichoscopy

Identifiers

PMID42808078
PMCPMC13619102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.